Antisense Therapeutics (ASX:ANP) continues to progress a research collaboration concerning the potential use of the investigational drug, ATL1102, in the diagnosis and treatment of ‘Long COVID’.
Key Points
- Long COVID is a potentially debilitating post-viral syndrome that is thought to occur in a proportion of patients following acute infection with SARS-CoV-2, the virus responsible for COVID-19, and in some cases can be long-lasting.
- A collaboration with Dr Igor Koralnik at the Northwestern Medicine Neuro-COVID Clinic in Chicago, IL commenced in 2022, focused on the potential uses of ATL1102 in this disease.
- The company previously reported promising data which identified potential biomarkers of long COVID and suggested the ability of ATL1102 to modulate aberrant immune cytokine responses in this patient group.
- This work has now been published in two peer-reviewed scientific journals and is the subject of an international patent application concerning the diagnosis of, and use of ATL1102 to treat, subjects with cognitive deficits.
“It is excellent to see this very high-quality work accepted for publication in two leading scientific journals,” Antisense CEO, Dr James Garner.
“These satisfying milestones conclude our work in this disease area for the time being, while the company focuses its attention on the ongoing international phase IIb study in Duchenne muscular dystrophy. However, the positive data, and the proprietary intellectual property that has been created, create some intriguing opportunities that we or a partner may return to at a future date.”
ATL1102 is currently the subject of an ongoing international phase IIb clinical trial in Duchenne muscular dystrophy, with data anticipated in 2H CY2024.
